^
    BIOMARKER:

    PD-L1 overexpression

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule




    Show legend

    Include preclinical:
    Non Small Cell Lung Cancer
    Lung Non-Small Cell Squamous Cancer
    Lung Non-Squamous Non-Small Cell Cancer
    Squamous Cell Carcinoma of Head and Neck
    Gastric Cancer
    Gastroesophageal Junction Adenocarcinoma
    Oral Cancer
    Melanoma
    Triple Negative Breast Cancer
    Urothelial Cancer
    Ovarian Cancer
    Solid Tumor
    Nasopharyngeal Carcinoma
    Prostate Cancer
    Glioblastoma
    Esophageal Squamous Cell Carcinoma
    Esophageal Adenocarcinoma
    Gastroesophageal Cancer
    Hepatocellular Cancer
    Bladder Cancer
    Lung Adenocarcinoma
    Non-Hodgkin’s Lymphoma
    Sarcoma
    Diffuse Large B Cell Lymphoma
    Thyroid Gland Anaplastic Carcinoma
    Biliary Tract Cancer
    Lung Cancer
    Follicular Lymphoma
    Mesothelioma
    Pancreatic Ductal Adenocarcinoma
    Clear Cell Renal Cell Carcinoma
    Soft Tissue Sarcoma
    Cervical Cancer
    Thyroid Gland Carcinoma
    Head and Neck Cancer
    Breast Cancer
    Renal Cell Carcinoma
    Malignant Pleural Mesothelioma
    Thymic Carcinoma
    Thymoma
    Cholangiocarcinoma
    Vulvar Cancer
    Peripheral T-cell Lymphoma
    Colorectal Cancer
    Acute Myelogenous Leukemia
    pembrolizumab
    durvalumab + tremelimumab
    nivolumab
    durvalumab
    nivolumab + ipilimumab
    bevacizumab + atezolizumab
    bevacizumab
    atezolizumab
    Immunotherapy
    EGFR inhibitor
    PD-L1 inhibitor
    R-CHOP
    R-GemOx
    GC
    PD1 inhibitor
    avelumab
    Immunotherapy + Angiogenesis inhibitor
    zimberelimab + AB154
    tislelizumab
    carboplatin + albumin-bound paclitaxel
    sintilimab
    cemiplimab-rwlc
    zimberelimab
    atezolizumab + enzalutamide capsule
    M7824
    cisplatin + pemetrexed
    carboplatin + pemetrexed
    cisplatin + albumin-bound paclitaxel
    carboplatin + gemcitabine
    durvalumab + cabozantinib tablet
    camrelizumab
    atezolizumab + RG6058
    SHR-1701
    pembrolizumab + lenvatinib
    olaparib
    PF-06801591
    zimberelimab + AB154 + AB928
    pembrolizumab + DS-1062a
    retifanlimab-dlwr
    camrelizumab + rivoceranib
    pembrolizumab + niraparib
    pembrolizumab + IO102-IO103
    dostarlimab-gxly
    nivolumab + nimotuzumab
    anlotinib + sintilimab
    BRL-201
    ipilimumab + cemiplimab-rwlc
    nivolumab + MGCD516
    anlotinib + cadonilimab
    toripalimab-tpzi
    ipilimumab
    avelumab + binimetinib
    pembrolizumab + nintedanib
    pazopanib
    paclitaxel
    docetaxel
    eftilagimod alpha
    avelumab + eftilagimod alpha
    trabectedin
    JNJ-63723283
    nivolumab + cetuximab
    ramucirumab
    pembrolizumab + SNK01
    pemetrexed
    pembrolizumab + INCB039110
    lenvatinib
    MGD013
    pembrolizumab + afatinib
    sintilimab + IBI-939
    carboplatin + docetaxel
    cemiplimab-rwlc + REGN3767
    trastuzumab
    nivolumab + bevacizumab
    pembrolizumab + bevacizumab
    nivolumab + ibrutinib
    geptanolimab
    cisplatin + paclitaxel
    nivolumab + LY2157299
    enzalutamide capsule
    pembrolizumab + capmatinib
    APL-502
    pembrolizumab + LY3500518
    sorafenib
    MGD006
    EPIM-001
    nivolumab + CDX 1127
    abiraterone acetate